Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 119
1.
Signal Transduct Target Ther ; 6(1): 183, 2021 05 17.
Article En | MEDLINE | ID: mdl-33994545

CK2 is a constitutively active Ser/Thr protein kinase, which phosphorylates hundreds of substrates, controls several signaling pathways, and is implicated in a plethora of human diseases. Its best documented role is in cancer, where it regulates practically all malignant hallmarks. Other well-known functions of CK2 are in human infections; in particular, several viruses exploit host cell CK2 for their life cycle. Very recently, also SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been found to enhance CK2 activity and to induce the phosphorylation of several CK2 substrates (either viral and host proteins). CK2 is also considered an emerging target for neurological diseases, inflammation and autoimmune disorders, diverse ophthalmic pathologies, diabetes, and obesity. In addition, CK2 activity has been associated with cardiovascular diseases, as cardiac ischemia-reperfusion injury, atherosclerosis, and cardiac hypertrophy. The hypothesis of considering CK2 inhibition for cystic fibrosis therapies has been also entertained for many years. Moreover, psychiatric disorders and syndromes due to CK2 mutations have been recently identified. On these bases, CK2 is emerging as an increasingly attractive target in various fields of human medicine, with the advantage that several very specific and effective inhibitors are already available. Here, we review the literature on CK2 implication in different human pathologies and evaluate its potential as a pharmacological target in the light of the most recent findings.


COVID-19 Drug Treatment , COVID-19 , Cardiovascular Diseases , Casein Kinase II , Cystic Fibrosis , Eye Diseases , Mental Disorders , Protein Kinase Inhibitors/therapeutic use , SARS-CoV-2 , COVID-19/enzymology , COVID-19/genetics , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/enzymology , Cardiovascular Diseases/genetics , Casein Kinase II/antagonists & inhibitors , Casein Kinase II/genetics , Casein Kinase II/metabolism , Cystic Fibrosis/drug therapy , Cystic Fibrosis/enzymology , Cystic Fibrosis/genetics , Eye Diseases/drug therapy , Eye Diseases/enzymology , Eye Diseases/genetics , Humans , Mental Disorders/drug therapy , Mental Disorders/enzymology , Mental Disorders/genetics , Mutation , Phosphorylation , Signal Transduction/drug effects , Signal Transduction/genetics
2.
Eye Contact Lens ; 46 Suppl 2: S57-S63, 2020 Mar.
Article En | MEDLINE | ID: mdl-32068662

OBJECTIVES: (1) To explore the role and significance of Matrix Metalloproteinase 9 (MMP-9), a proteolytic enzyme, in various ocular surface diseases of inflammatory, infectious, and traumatic etiology (2), to further elucidate the molecular mechanisms responsible for its overexpression in ocular surface disease states, and (3) to discuss possible targets of therapeutic intervention. METHODS: A literature review was conducted of primary sources from 1995 onward using search results populated from the US National Library of Medicine search database. RESULTS: MMP-9 overexpression has been found in in vitro and in vivo models of dry eye disease (DED), corneal ulceration, microbial keratitis, corneal neovascularization, ultraviolet light-induced radiation, and a host of additional surface pathologies. MMP-9 is involved in an intricate signal transduction cascade that includes induction by many proinflammatory molecules including interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-a), nuclear factor kappa light chain enhancer of activated B cells (NF-kB), platelet-activating factor, activator protein 1 (AP-1), and transforming growth factor beta (TGF-B). MMP-9 expression is blunted by a diverse array of molecular factors, such as tissue inhibitors of metalloproteinases, cyclosporine A (CyA), PES_103, epigalloccatechin-3-gallate (EGCG), N-acetylcysteine (NaC), ascorbate, tetracyclines, and corticosteroids. Inhibition of MMP-9 frequently led to improvement of ocular surface disease. CONCLUSIONS: Novel insights into the mechanistic action of MMP-9 provide potential for new therapeutic modulations of ocular surface diseases mediated by its overexpression.


Eye Diseases/enzymology , Matrix Metalloproteinase 9/metabolism , Biomarkers/metabolism , Humans , Signal Transduction
3.
Indian J Ophthalmol ; 65(10): 979-983, 2017 Oct.
Article En | MEDLINE | ID: mdl-29044064

PURPOSE: Many studies include elevated activity of angiotensin-converting enzyme (ACE) in serum in sarcoidosis and in ocular sarcoidosis as well, but there are only a few analyzing ACE activities in aqueous humor. The aim of this study is to illuminate the diagnostic value of ACE in aqueous humor in patients with ocular sarcoidosis. METHODS: We analyzed twenty patients with ocular sarcoidosis and 18 patients with nonocular involvement. All patients have biopsy-positive sarcoidosis of the lungs and/or mediastinal lymph nodes. Blood samples for ACE serum levels were obtained from all patients. Aqueous humor samples were taken by paracentesis with a 25-gauge needle in local anesthesia. With appropriate statistical tests, we compared ACE activity in serum and aqueous humor in patients with and without ocular sarcoidosis. RESULTS: The majority of our patients with ocular sarcoidosis were female (12/20), also in the group with systemic sarcoidosis and without ocular involvement (12/6). Mean age of the whole analyzed group of sarcoidosis patients was 45 ± 6 years. There is no statistically significant difference in ACE activity in serum between two groups of patients (with and without ocular sarcoidosis). There is statistically significant difference in ACE activity in aqueous humor among patients with ocular and nonocular sarcoidosis. ACE activity in aqueous humor is significantly higher in patients with ocular sarcoidosis. CONCLUSION: Increased ACE activity in aqueous humor can point to a diagnosis of ocular sarcoidosis, without the need for ocular biopsy.


Aqueous Humor/enzymology , Eye Diseases/diagnosis , Peptidyl-Dipeptidase A/metabolism , Sarcoidosis/diagnosis , Biomarkers/metabolism , Biopsy , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Eye Diseases/enzymology , Female , Humans , Male , Middle Aged , Sarcoidosis/enzymology , Spectrophotometry
4.
Life Sci ; 145: 274-83, 2016 Jan 15.
Article En | MEDLINE | ID: mdl-26475762

AIMS: Although epidemiological studies have investigated associations between occupational pesticide exposures and different adverse health outcomes, they have rarely assessed individuals at two time-points of a same crop season with different pesticide use. MATERIAL AND METHODS: Clinical symptoms, physical examination signs, hematological and clinical chemistry parameters were measured in 189 intensive agriculture workers and 91 healthy control subjects from Almeria coastline (Southeastern Spain) to evaluate potential effects of pesticide exposure. KEY FINDINGS: Greenhouse workers showed an increased risk of ocular and skin signs relative to controls at the period of high pesticide exposure (OR: 4.80 and 2.87, respectively); however, no differences were observed for clinical symptoms. A greater risk for ECG changes (OR: 3.35) and altered spirometry (OR: 5.02) was found at the period of low exposure. Erythrocyte acetylcholinesterase was significantly decreased in greenhouse workers relative to controls in both periods. Assessment of hematological parameters revealed increased counts of erythrocytes, leukocytes, platelets and hemoglobin in greenhouse workers relative to controls, and also in the period of high versus low pesticide exposure. Changes in clinical chemistry parameters included decreased levels of glucose, creatinine, total cholesterol, triglyceride and alkaline phosphatase in greenhouse workers relative to controls; however, these parameters were raised in the period of high versus low pesticide exposure. SIGNIFICANCE: These findings suggest that chronic occupational exposure to pesticides of lower toxicity than former compounds under integrated production systems elicit mild toxic effects, particularly targeting the skin and eyes, as well as subtle subclinical (biochemical) changes of unknown long-term consequences.


Agricultural Workers' Diseases/chemically induced , Eye Diseases/chemically induced , Occupational Exposure/adverse effects , Pesticides/adverse effects , Skin Diseases/chemically induced , Acetylcholinesterase/metabolism , Adult , Agricultural Workers' Diseases/blood , Agricultural Workers' Diseases/enzymology , Agriculture/methods , Blood Cell Count , Eye Diseases/blood , Eye Diseases/enzymology , Farmers , Female , Humans , Male , Middle Aged , Skin Diseases/blood , Skin Diseases/enzymology , Spain/epidemiology
5.
J Ocul Pharmacol Ther ; 31(2): 93-9, 2015 Mar.
Article En | MEDLINE | ID: mdl-25347151

PURPOSE: We aimed to investigate the safety, tolerability, and systemic diffusion of a single escalating dose of XG-102 (a 31-D-amino-acid peptide inhibiting JNK pathway activation), administered subconjunctivally in the treatment of post-surgery or post-trauma intraocular inflammation. METHODS: This is a dose-escalating, tolerance Phase Ib study. Twenty patients with post-surgery or post-traumatic intraocular inflammation were assigned to 1 of the 4 dose escalating (45, 90, 450, or 900 µg XG-102) groups of 5 patients each. Patients were evaluated at 24, 48 h, 8, and 28 days following the administration of XG-102, including laboratory tests, standard eye examinations, vital signs, and occurrence of adverse events. A single plasma quantification of XG-102 was performed 30 min after administration, according to previous pharmacokinetics studies performed on volunteers. RESULTS: A total of 17 non-serious adverse events, considered unrelated to the study treatment, were reported for 10 patients. The adverse event incidence was not related to the drug dose. All patients experienced a decrease in intraocular inflammation as of 24 h post-administration and this decrease was sustained up to 28 days thereafter. No patient required local injection or systemic administration of corticoids following the administration of XG-102. XG-102 was undetectable in the first 3 dose groups. In the fourth-dose group (900 µg) the XG-102 plasma levels were above the limit of detection for 3 patients and above the limit of quantification for 1 patient. CONCLUSIONS: In this first clinical trial using XG-102, administered as a single subconjunctival injection as adjunct therapy, in patients with recent post-surgery or post-trauma intraocular inflammation is safe and well tolerated. Further studies are required to evaluate its efficacy.


Eye Diseases/drug therapy , Inflammation/drug therapy , MAP Kinase Kinase 4/antagonists & inhibitors , MAP Kinase Signaling System/drug effects , Peptides/administration & dosage , Peptides/adverse effects , Adolescent , Aged , Dose-Response Relationship, Drug , Eye Diseases/blood , Eye Diseases/enzymology , Female , Humans , Inflammation/blood , Inflammation/enzymology , Injections, Intraocular , MAP Kinase Kinase 4/metabolism , Male , Middle Aged , Peptides/blood , Postoperative Complications/drug therapy
6.
J Ocul Pharmacol Ther ; 30(8): 605-14, 2014 Oct.
Article En | MEDLINE | ID: mdl-25280175

Ocular diseases such as cataract, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are the leading causes of blindness. The elderly population is at particular risk of developing one or more of these age-related ocular diseases. By virtue of multiple bioactivities, effort has been made to develop dietary flavonoids as complimentary therapies for ocular disorders. Dietary intake of flavonoids has been reported to reduce the risk of cataract and AMD. This review focuses on the main flavones baicalein, baicalin, and wogonin isolated from the Chinese medicinal herb, Scutellariae radix (SR), which has been widely used in Asian countries for the treatment of many diseases. Interest in SR has grown recently following new findings that suggest multiple routes of therapeutic action. This review will summarize the diverse pharmacological properties, therapeutic roles, and mechanisms of these flavones of SR in cellular and animal models of ocular diseases.


Drugs, Chinese Herbal/therapeutic use , Eye Diseases/drug therapy , Flavanones/therapeutic use , Flavonoids/therapeutic use , Animals , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/pharmacology , Eye Diseases/enzymology , Eye Diseases/metabolism , Eye Diseases/pathology , Flavanones/isolation & purification , Flavanones/pharmacology , Flavonoids/isolation & purification , Flavonoids/pharmacology , Humans , Molecular Structure , Scutellaria baicalensis/chemistry
7.
Invest Ophthalmol Vis Sci ; 55(10): 6851-6860, 2014 Sep 23.
Article En | MEDLINE | ID: mdl-25249600

PURPOSE: The incidence of blindness is increasing, in part, because of abnormal ocular neovascularization. Anti-VEGF therapies have yielded impressive results; however, they are not a cure for blindness. Recently, metallothioneins (MTs) 1 and 2 have been implicated in the process of angiogenesis. Therefore, we investigated whether MT-1 and MT-2 were also involved in ocular neovascularization. METHODS: The concentrations of MT-1 and MT-2 (hereafter MT-1/2) were observed by ELISA. We examined the role of MT-1/2 in ocular neovascularization by using both an oxygen-induced retinopathy (OIR) model and a laser-induced choroidal neovascularization (CNV) model. We investigated the localization of MT-1/2 in retina. Furthermore, we investigated the expression of hypoxia-inducible factor (HIF)-1α and VEGF in OIR. In vitro, we investigated the degradation of HIF-1α. RESULTS: The MT-1/2 were significantly elevated in proliferative diabetic retinopathy patients. Ocular neovascularization, which was induced in both the OIR model and the CNV model, was decreased in MT-1/2 knockout (KO) mice. We confirmed that although MT-1/2 was expressed throughout the murine retina, its expression levels were highest in the endothelial cells. Further, OIR enhanced MT-1/2 expression in the retina. Interestingly, in the OIR model, both HIF-1α and VEGF levels were significantly decreased in the retina of MT-1/2 KO mice. In addition, we found that knockdown of MT-1/2 accelerated ubiquitination of HIF-1α. CONCLUSIONS: These results indicate that MT-1/2 are involved in retinal and choroidal neovascularization, and that MT-1/2 might be a new therapeutic target in diseases in which ocular angiogenesis is implicated.


Eye Diseases/enzymology , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , Neovascularization, Pathologic/enzymology , Aged , Animals , Blotting, Western , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Eye Diseases/pathology , Female , Fluorescein Angiography , Fundus Oculi , Humans , Immunoblotting , Immunohistochemistry , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Neovascularization, Pathologic/pathology , Vitreous Body/enzymology
8.
Hum Mol Genet ; 23(22): 6129-36, 2014 Nov 15.
Article En | MEDLINE | ID: mdl-24963161

Corneal curvature (CC) measures the steepness of the cornea and is an important parameter for clinically diseases such as astigmatism and myopia. Despite the high heritability of CC, only two associated genes have been discovered to date. We performed a three-stage genome-wide association study meta-analysis in 12 660 Asian individuals. Our Stage 1 was done in multiethnic cohorts comprising 7440 individuals, followed by a Stage 2 replication in 2473 Chinese and Stage 3 in 2747 Japanese. The SNP array genotype data were imputed up to the 1000 Genomes Project Phase 1 cosmopolitan panel. The SNP association with the radii of CC was investigated in the linear regression model with the adjustment of age, gender and principal components. In addition to the known genes, MTOR (also known as FRAP1) and PDGFRA, we discovered two novel genes associated with CC: CMPK1 (rs17103186, P = 3.3 × 10(-12)) and RBP3 (rs11204213 [Val884Met], P = 1.1 × 10(-13)). The missense RBP3 SNP, rs11204213, was also associated with axial length (AL) (P = 4.2 × 10(-6)) and had larger effects on both CC and AL compared with other SNPs. The index SNPs at the four indicated loci explained 1.9% of CC variance across the Stages 1 and 2 cohorts, while 33.8% of CC variance was explained by the genome-wide imputation data. We identified two novel genes influencing CC, which are related to either corneal shape or eye size. This study provides additional insights into genetic architecture of corneal shape.


Asian People/genetics , Cornea/chemistry , Eye Diseases/genetics , Eye Proteins/genetics , Retinol-Binding Proteins/genetics , Adult , Aged , Child , China , Cohort Studies , Cornea/enzymology , Cornea/metabolism , Eye Diseases/enzymology , Female , Genetic Predisposition to Disease , Genome-Wide Association Study , Humans , Japan , Male , Middle Aged , Nucleoside-Phosphate Kinase , Polymorphism, Single Nucleotide
9.
Front Biosci (Landmark Ed) ; 19(8): 1456-67, 2014 06 01.
Article En | MEDLINE | ID: mdl-24896365

ADAMTS-18 is a member of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family of proteases, which are known to play important roles in development, angiogenesis and coagulation; dysregulation and mutation of these enzymes have been implicated in many disease processes, such as inflammation, cancer, arthritis and atherosclerosis. Mutations of ADAMTS-18 have been linked to abnormal early eye development and reduced bone mineral density. In this review, we briefly summarize the structural organization and the expression of ADAMTS-18. We will also focus on the emerging role of ADAMTS-18 in several pathophysiological conditions which include: hematological diseases, tumorgenesis, osteogenesis, eye-related diseases, central nervous system disorders, and last but not least a research perspective of ADAMTS-18 and its potential as a promising diagnostic and therapeutic target.


ADAM Proteins/genetics , Genetic Predisposition to Disease/genetics , Models, Genetic , Mutation , ADAM Proteins/metabolism , ADAMTS Proteins , Bone Diseases/enzymology , Bone Diseases/genetics , Eye Diseases/enzymology , Eye Diseases/genetics , Hematologic Diseases/enzymology , Hematologic Diseases/genetics , Humans , Neoplasms/enzymology , Neoplasms/genetics
10.
Intern Med ; 51(21): 3077-9, 2012.
Article En | MEDLINE | ID: mdl-23124154

We herein report a case of ocular myasthenia gravis (MG) that was highly positive for anti-muscle-specific tyrosine kinase (MuSK) antibodies. The examined patient exhibited bilateral ptosis and lateral gaze palsy without any generalized symptoms and was diagnosed with ocular MG with anti-MuSK antibodies. She responded to treatment with prednisolone and immunosuppressants and experienced only ocular symptoms for four years and eight months after onset. Ocular MG with anti-MuSK antibodies lasting for a long term has rarely been described. Our findings suggest that it may be reasonable to test for the presence of anti-MuSK antibodies in patients who present with external ophthalmoplegia.


Autoantibodies/blood , Eye Diseases/immunology , Myasthenia Gravis/immunology , Receptor Protein-Tyrosine Kinases/immunology , Receptors, Cholinergic/immunology , Adult , Eye Diseases/complications , Eye Diseases/diagnosis , Eye Diseases/enzymology , Female , Humans , Myasthenia Gravis/complications , Myasthenia Gravis/diagnosis , Myasthenia Gravis/enzymology , Ophthalmoplegia/etiology , Ophthalmoplegia/immunology , Time Factors
11.
J Immunol ; 189(3): 1220-7, 2012 Aug 01.
Article En | MEDLINE | ID: mdl-22745380

Subpopulations of pathogenic or nonpathogenic Th17 cells were reported to develop when presensitized CD4 cells were activated with their target Ag during polarization by either IL-23 or IL-6 and TGF-ß, respectively. In this study, we generated two Th17 subpopulations by using a system in which naive CD4 cells from TCR transgenic mice specific to hen egg lysozyme (HEL) are polarized with IL-6/TGF-ß and, concurrently, are activated either with HEL presented by APCs, or with anti-CD3/CD28 Abs. Only the former cells were pathogenic, inducing inflammation in eyes expressing HEL. Naive CD4 cells activated by the anti-CD3/CD28 Abs acquired pathogenicity, however, when cocultured with HEL/APC. Importantly, the naive CD4 cells did not acquire pathogenicity when cocultured with APCs stimulated with LPS or when separated from the HEL-presenting cells by a semipermeable membrane. Unlike with presensitized Th17, soluble IL-23 does not participate in pathogenicity acquisition by naive CD4 cells; no pathogenicity was induced by adding IL-23 to cultures activated with anti-CD3/CD28 Abs. Furthermore, Abs against IL-23 or IL-23R did not inhibit acquisition of pathogenicity in cultures of naive CD4 cells activated by HEL/APC. Our data thus show that, unlike presensitized CD4 cells, naive CD4 cells polarized toward Th17 phenotype acquire pathogenicity only by direct interaction with APCs presenting the Ag, with no apparent involvement of soluble IL-23. We suggest that the Th17 lymphocytes derived from naive CD4 cells participate in pathogenic and other immune processes, along with the IL-23-dependent Th17 cells.


Antigen-Presenting Cells/immunology , CD4-Positive T-Lymphocytes/immunology , Cell Communication/immunology , Cell Lineage/immunology , Muramidase/metabolism , Th17 Cells/immunology , Animals , Antigen-Presenting Cells/metabolism , CD4-Positive T-Lymphocytes/enzymology , CD4-Positive T-Lymphocytes/pathology , Cells, Cultured , Coculture Techniques , Dendritic Cells/immunology , Eye Diseases/enzymology , Eye Diseases/immunology , Eye Diseases/pathology , Inflammation/enzymology , Inflammation/immunology , Inflammation/pathology , Interleukin-23/metabolism , Mice , Mice, Transgenic , Muramidase/adverse effects , Muramidase/immunology , Th17 Cells/enzymology , Th17 Cells/pathology
12.
Curr Eye Res ; 37(11): 955-60, 2012 Nov.
Article En | MEDLINE | ID: mdl-22720721

Heme oxygenase (HO) catabolizes heme into three products: carbon monoxide (CO), biliverdin/bilirubin and free iron. Two distinct isoforms of HO have been identified: an inducible isozyme HO-1 and a constitutively expressed isozyme HO-2, which participate in a variety of physiological and pathophysiological processes. A growing body of evidence indicates that HO activation plays a variety of roles in several ocular diseases, functioning protectively by reducing oxidative injury, attenuating the inflammatory response, and inhibiting cell apoptosis. This review focuses on the current understanding of the physiological significance of HO and its putative roles in the ocular disease. Possible therapeutic strategies involving HO in the treatment of ocular disease are discussed.


Apoptosis , Cytoprotection/physiology , Eye Diseases/enzymology , Heme Oxygenase (Decyclizing)/physiology , Animals , Eye Diseases/pathology , Humans
13.
Prog Mol Biol Transl Sci ; 109: 347-96, 2012.
Article En | MEDLINE | ID: mdl-22727427

The ubiquitin-proteasome pathway (UPP) plays important roles in many cellular functions, such as protein quality control, cell cycle control, and signal transduction. The selective degradation of aberrant proteins by the UPP is essential for the timely removal of potential cytotoxic damaged or otherwise abnormal proteins. Conversely, accumulation of the cytotoxic abnormal proteins in eye tissues is etiologically associated with many age-related eye diseases such as retina degeneration, cataract, and certain types of glaucoma. Age- or stress-induced impairment or overburdening of the UPP appears to contribute to the accumulation of abnormal proteins in eye tissues. Cell cycle and signal transduction are regulated by the conditional UPP-dependent degradation of the regulators of these processes. Impairment or overburdening of the UPP could also result in dysregulation of cell cycle control and signal transduction. The consequences of the improper cell cycle and signal transduction include defects in ocular development, wound healing, angiogenesis, or inflammatory responses. Methods that enhance or preserve UPP function or reduce its burden may be useful strategies for preventing age-related eye diseases.


Eye Diseases/enzymology , Eye Diseases/etiology , Eye Proteins/metabolism , Proteasome Endopeptidase Complex/metabolism , Signal Transduction , Ubiquitin/metabolism , Animals , Eye Diseases/pathology , Humans , Oxidative Stress
15.
J Pediatr Ophthalmol Strabismus ; 48(3): 157-62, 2011.
Article En | MEDLINE | ID: mdl-20506967

PURPOSE: To describe pediatric patients with uveitis diagnosed as having sarcoidosis. METHODS: Medical records of pediatric patients evaluated between 1987 and 2008 were reviewed to identify those with ocular inflammation in whom a diagnosis of sarcoidosis was considered. A classification system including ocular findings and results of laboratory testing was devised and used to classify likelihood of sarcoidosis. RESULTS: Four hundred sixty children younger than 17 years were evaluated. Based on the classification system designed, 13 patients (2.8%) had probable, presumed, or definite sarcoidosis. The mean age was 11.6 years (range: 5 to 16 years). Elevated angiotensin-converting enzyme was measured in 6 patients and lysozyme in 5 patients. Five of 12 patients in whom chest imaging was performed had signs of sarcoidosis. Anterior segment involvement was non-granulomatous more often than granulomatous. Seven patients had multifocal choroiditis and 4 patients had retinal periphlebitis. CONCLUSION: Ocular sarcoidosis is uncommon in children, even at a tertiary referral center. Pulmonary involvement was detected in slightly less than half of the patients who had imaging, in contrast to previous reports of almost universal lung involvement in children 8 to 15 years old. The classification system of presumed, probable, and definite sarcoidosis presented may be useful in clinical practice.


Eye Diseases/complications , Sarcoidosis/complications , Uveitis/etiology , Adolescent , Biopsy , Child , Child, Preschool , Eye Diseases/diagnosis , Eye Diseases/enzymology , Female , Humans , Male , Muramidase/blood , Peptidyl-Dipeptidase A/blood , Sarcoidosis/diagnosis , Sarcoidosis/enzymology , Uveitis/diagnosis , Uveitis/enzymology
16.
J Inherit Metab Dis ; 33(5): 619-24, 2010 Oct.
Article En | MEDLINE | ID: mdl-20821055

Newborn screening for Fabry disease in Taiwan Chinese has revealed a high incidence of the late-onset GLA mutation IVS4 + 919G→A (∼1 in 1,500-1,600 males). We studied 94 adults with this mutation [22 men, 72 women; mean age: men 57.8 ± 6.0 (range 42-68), women 39.1 ± 14.1 years (range 19-82)]. Plasma α-galactosidase A activity assay was 10.4 ± 11.2% of normal in the men and 48.6 ± 19.5% of normal in the women. Echocardiography in 90 of the adults revealed left ventricular hypertrophy (LVH) in 19 (21%), including 14 of 21 men (67%) and 5 of 69 women (7%). Microalbuminuria, based on the urine albumin-to-creatinine ratio measured on at least two occasions, was present in 17 of 86 subjects (20%) (men: 5/20, 25%; women 12/66, 18%). At least one ocular manifestation consistent with Fabry disease was present in 41 of 52 subjects (79%) who underwent ophthalmologic examination, including 8 (15%) with conjunctival vessel tortuosity, 15 (29%) with cornea verticillata, 10 (19%) with Fabry cataract, and 34 (65%) with retinal vessel tortuosity. Among subjects over 40 years of age, men were more likely than women to have LVH [14/21 (67%) vs 5/25 (20%), p < 0.001]. Cardiovascular, renal and ocular abnormalities are highly prevalent in adult Taiwan Chinese subjects with the Fabry mutation IVS4 + 919G→A. Our findings contribute to the limited understanding of the course of this late-onset disease variant and underscore the need for close follow up in such patients.


Asian People/genetics , Clinical Enzyme Tests , Fabry Disease/genetics , Mutation , alpha-Galactosidase/genetics , Adult , Aged , Aged, 80 and over , Albuminuria/enzymology , Albuminuria/genetics , Biomarkers/blood , China/ethnology , DNA Mutational Analysis , Diagnostic Techniques, Ophthalmological , Echocardiography , Eye Diseases/enzymology , Eye Diseases/genetics , Fabry Disease/diagnosis , Fabry Disease/enzymology , Fabry Disease/ethnology , Female , Genetic Predisposition to Disease , Humans , Hypertrophy, Left Ventricular/enzymology , Hypertrophy, Left Ventricular/genetics , Male , Middle Aged , Phenotype , Taiwan/epidemiology , Urinalysis , Young Adult , alpha-Galactosidase/blood
17.
J Inherit Metab Dis ; 33 Suppl 3: S257-62, 2010 Dec.
Article En | MEDLINE | ID: mdl-20596894

Metachromatic leukodystrophy (MLD) is a lysosomal disorder caused by arylsulfatase A (ARSA) deficiency. It is classified into three forms according to the age of onset of symptoms (late infantile, juvenile, and adult). We carried out a cross-sectional and retrospective study, which aimed to determine the epidemiological, clinical, and biochemical profile of MLD patients from a national reference center for Inborn Errors of Metabolism in Brazil. Twenty-nine patients (male, 17) agreed to participate in the study (late infantile form: 22; juvenile form: 4; adult form: 1; asymptomatic: 2). Mean ages at onset of symptoms and at biochemical diagnosis were, respectively, 19 and 39 months for late infantile form and 84.7 and 161.2 months for juvenile form. The most frequently reported first clinical symptom/sign of the disease was gait disturbance and other motor abnormalities (72.7%) for late infantile form and behavioral and cognitive alterations (50%) for juvenile form. Leukocyte ARSA activity level did not present significant correlation with the age of onset of symptoms (r = -0.09, p = 0.67). Occipital white matter and basal nuclei abnormalities were not found in patients with the late infantile MLD. Our results suggest that there is a considerable delay between the age of onset of signs and symptoms and the diagnosis of MLD in Brazil. Correlation between ARSA activity and MLD clinical form was not found. Further studies on the epidemiology and natural history of this disease with larger samples are needed, especially now when specific treatments should be available in the near future.


Cerebroside-Sulfatase/deficiency , Leukocytes/enzymology , Leukodystrophy, Metachromatic/diagnosis , Adolescent , Age of Onset , Biomarkers/blood , Biomarkers/urine , Brazil/epidemiology , Cerebroside-Sulfatase/blood , Child , Child, Preschool , Cross-Sectional Studies , Diagnostic Techniques, Ophthalmological , Disease Progression , Electroencephalography , Eye Diseases/diagnosis , Eye Diseases/enzymology , Eye Diseases/epidemiology , Female , Gait Disorders, Neurologic/diagnosis , Gait Disorders, Neurologic/enzymology , Gait Disorders, Neurologic/epidemiology , Humans , Infant , Leukodystrophy, Metachromatic/drug therapy , Leukodystrophy, Metachromatic/enzymology , Leukodystrophy, Metachromatic/epidemiology , Leukoencephalopathies/diagnosis , Leukoencephalopathies/enzymology , Leukoencephalopathies/epidemiology , Magnetic Resonance Imaging , Male , Mental Disorders/diagnosis , Mental Disorders/enzymology , Mental Disorders/epidemiology , Predictive Value of Tests , Prognosis , Retrospective Studies , Sulfoglycosphingolipids/urine , Time Factors , Young Adult
18.
Biochimie ; 92(6): 611-9, 2010 Jun.
Article En | MEDLINE | ID: mdl-20403410

Phospholipases A(2) (PLA(2)s) and its generation of second messengers play an important role in signal transduction, cell proliferation, cell survival and gene expression. At low concentrations mediators of PLA(2) activity have a variety of physiological effects whereas high levels of PLA(2) and its metabolites are generated during pathological conditions. The eye is an immunoprivileged organ with tight barriers and a complex interplay among various cell types. Overall, vision is a complex process which requires a clear corneal surface and lens, and thereby a clear pathway through the eye into the retina. In the retina the photoreceptors transmit light into neuronal signals that are finally transferred to the brain to perceive an image. Growing knowledge of a role of PLA(2) in ocular diseases appears and the present review aims to summarize the vast literature on PLA(2) in the normal eye as well as during pathological conditions.


Eye Diseases/enzymology , Phospholipases A2/metabolism , Animals , Corneal Diseases/enzymology , Corneal Diseases/metabolism , Homeostasis , Humans , Neurons/metabolism , Photoreceptor Cells/metabolism , Retina/enzymology , Retina/metabolism , Signal Transduction
19.
Mol Cell Biochem ; 338(1-2): 133-41, 2010 May.
Article En | MEDLINE | ID: mdl-19967549

Since its initial discovery as Ca(2+)/calmodulin (CaM)-dependent serine/threonine protein phosphatase, calcineurin (CaN) has been extensively studied in many mammalian tissues. CaN has been shown to be involved in various biological and Ca(2+)-dependent signal transduction pathways. Over the last decade, our laboratory has been interested and has carried out numerous experiments on this specific protein phosphatase. While, a lot of research has been performed studying CaN's involvement in ischemia, the immune system, and various mammalian tissues, not much is known about the potential role of CaN in various eye diseases. This review focuses on the studies that have been carried out in our laboratory on CaN, and specifically CaN's involvement in the eye. We demonstrated that CaN is localized in various eye tissues (cornea, iris, ciliary body, vitreous body, retina, choroid, sclera, and optic nerve) and that both its protein expression and activity were observed in high amounts in the retina, optic nerve and cornea. Recently, we have cloned and characterized the CaN A and B subunits in the bovine retina. These initial findings suggest that CaN may play a potential role in visual transduction and various ocular diseases, including cancer.


Calcineurin/metabolism , Eye Diseases/enzymology , Animals , Apoptosis/physiology , Calcineurin/genetics , Calmodulin/metabolism , Eye/anatomy & histology , Eye/enzymology , Eye Diseases/pathology , Humans , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Subunits/genetics , Protein Subunits/metabolism , Tissue Distribution , Vision, Ocular/physiology
...